Clinical Trials on Chronische myeloïde leukemie

Total 7762 results

Shenzhen Second People's Hospital

Recruiting

Azacytidine + HAG Regimen vs. Azacytidine for Elderly Patients With Newly Diagnosed Myeloid Malignancy

Acute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic Leukemia

China
Pfizer

Completed

Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database

Chronic Myeloid Leukaemia

Hungary
Pfizer
pH Associates

Completed

A Study To Describe The Real World Use Of Bosutinib In The UK And Netherlands

Chronic Myeloid Leukaemia

United Kingdom
Novartis Pharmaceuticals

Completed

Real-World Disease Management and Outcomes in Chronic Myeloid Leukaemia

Chronic Myeloid Leukaemia

United Kingdom
Cardiff University
Experimental Cancer Medicine Centres; Leukaemia & Lymphoma Research Group

Completed

A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome. (AML18 Pilot)

High Risk Myelodysplastic Syndrome | Acute Myeloid Leukaemia

United Kingdom
University College, London
Bloodwise

Completed

Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers (UK-Haplo)

Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | Myelodysplastic Syndrome | Acute Myeloid Leukaemia | Chronic Lymphocytic Leukaemia | Acute Lymphoblastic Leukaemia | Chronic Myeloid Leukaemia | Acquired Bone Marrow Failure Syndromes | Other Haematological Malignancies; Unrelated HSCT Indicated

United Kingdom
Institut Paoli-Calmettes
INATHERYS

Recruiting

Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia (INA03)

Acute Lymphoblastic Leukemia, in Relapse | Acute Myeloid Leukemia, in Relapse | Mixed Phenotype Acute Leukemia | Acute Lymphoblastic Leukemia Recurrent | Acute Myeloid Leukaemia Recurrent

France
Peter MacCallum Cancer Centre, Australia
GlaxoSmithKline; Celgene Corporation

Completed

A Single Arm Pilot Study of Azacitidine in Myelodysplastic Syndromes (MDS) / Acute Myeloid Leukaemia (AML), With Eltrombopag Support for Thrombocytopenia (Aza-E)

Myelodysplastic Syndromes (MDS) | Acute Myeloid Leukaemia (AML)

Australia
medac GmbH
Synteract, Inc.

Recruiting

Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics

Myelodysplastic Syndrome (MDS) | Acute Myeloid Leukaemia (AML) | Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

United States
Epizyme, Inc.
Celgene Corporation

Completed

A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene

Acute Myeloid Leukemia | Leukemia | Acute Lymphocytic Leukemia | Acute Leukemias

United States, Canada
University of Pennsylvania

Active, not recruiting

CD123 Redirected T Cells for AML in Pediatric Subjects

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, Pediatric

United States
Betta Pharmaceuticals Co., Ltd.

Not yet recruiting

A Study of MRX2843 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia Leukemia

China
Washington University School of Medicine

Withdrawn

Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML

Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid Leukemia

United States
C. Babis Andreadis
Gateway for Cancer Research; AVEO Pharmaceuticals, Inc.

Terminated

Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML

Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid Leukemia

United States
Oryzon Genomics S.A.

Recruiting

Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+) (FRIDA)

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

United States
University Hospital, Antwerp

Recruiting

Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

Belgium
Medical College of Wisconsin

Recruiting

Venetoclax to Augment Epigenetic Modification and Chemotherapy

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

United States
Massachusetts General Hospital
Exelixis

Completed

Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid Leukemia

United States
Chinese PLA General Hospital

Unknown

Treatment of Relapsed and/or Chemotherapy Refractory CD33 Positive Acute Myeloid Leukemia by CART-33 (CART33)

Relapsed Adult Myeloid Leukemia | Chemotherapy Refractory Adult Myeloid Leukemia

China
Yale University
Pfizer

Terminated

GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia

ACUTE MYELOID LEUKEMIA

United States
Peking University People's Hospital
Beijing JD Biotech Co. LTD.

Recruiting

Off-the-shelf CD123 CAR-NK for R/R AML

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

China
Xuzhou Medical University

Recruiting

Administration of Anti-siglec-6 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

China
Bio-Path Holdings, Inc.

Recruiting

A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

United States
Institute of Hematology & Blood Diseases Hospital
Bejing Institute for Stem Cell and Regenerative Medicine; Institute for Stem...

Recruiting

Safety and Preliminary Efficacy of JK500 Cell Injection in Relapsed/Refractory Pediatric Acute Myeloid Leukemia

Refractory Leukemia | Relapsed Leukemia | Acute Myeloid Leukemia, Childhood

China
Advesya SAS

Not yet recruiting

An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia (RESOLVE AML001)

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

France, Sweden, Spain, Germany
German Cancer Research Center
University Hospital Heidelberg; University Hospital Dresden

Not yet recruiting

Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients With AML (GALAXY33)

Relapsed/Refractory Acute Myeloid Leukemia (AML)

Germany
Georgetown University
National Heart, Lung, and Blood Institute (NHLBI); Jazz Pharmaceuticals

Recruiting

Phase IB/II of CPX-351 for Relapse Prevention in AML

Acute Myeloid Leukemia (AML) in Remission

United States
Keystone Nano, Inc
Milton S. Hershey Medical Center; University of Virginia

Not yet recruiting

Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (KNAN2001)

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory

United States
Centre Leon Berard
NETRIS Pharma

Recruiting

Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX] (AML-NET)

Acute Myeloid Leukemia Refractory

France
Servier Affaires Médicales

Recruiting

An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.

Acute Myeloid Leukemia (AML)

Netherlands, Italy, Austria, France
Moleculin Biotech, Inc.

Recruiting

Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML)

Leukemia, Myeloid, Acute

Italy, Poland
guomei

Recruiting

Microtransplantation Combined With Azacytidine to Improve the Efficacy of EAML

Adult Acute Myeloid Leukemia

China
Polaris Group

Recruiting

Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia

Acute Myeloid Leukemia, Adult

United States
The First Affiliated Hospital of Soochow University

Recruiting

Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk Features

Acute Myeloid Leukemia, Adult

China
PETHEMA Foundation

Recruiting

Molecular Diagnostic Platform for AML

Acute Myeloid Leukemia (AML)

Spain
Federal Research Institute of Pediatric Hematology...
Physicians, Innovations, Science for Children Fund

Recruiting

A Prospective Multicenter Clinical Trial of MRD-based Treatment Strategy in Children and Young Adults With AML

Acute Myeloid Leukemia, Childhood

Russian Federation
Takeda

Active, not recruiting

A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy (PEVENAZA)

Acute Myeloid Leukemia (AML)

United States, France, Italy, Poland, Canada
University of Ulm

Completed

Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™)

Acute Myeloid Leukemia (AML)

Germany, Austria
AbbVie

Active, not recruiting

A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

Acute Myeloid Leukemia (AML)

United States, Argentina, Australia, Belgium, Brazil, Canada, China, Czechia, France, Germany, Greece, Hungary, Ireland, Japan, Korea, Republic of, Mexico, New Zealand, Norway, Puerto Rico, Russian Federation, South Africa, Spain, T... and more
AbbVie
Genentech, Inc.

Active, not recruiting

Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China

Acute Myeloid Leukemia (AML)

China
Daiichi Sankyo Co., Ltd.

Completed

Study of Quizartinib in Combination With Standard Therapies in Chinese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML)

China
AbbVie
Sumitomo Pharma Oncology, Inc.

Completed

A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML)

United States, Germany, United Kingdom
Astellas Pharma Global Development, Inc.

Completed

Treatment Patterns and Key Healthcare Resource Use in Acute Myeloid Leukemia (AML) With or Without FMS-like Tyrosine Kinase-3 (FLT3) Mutation Study Based on Retrospective Chart Review

Acute Myeloid Leukemia (AML)

United States
AbbVie

Terminated

A Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Participants With Relapsed/Refractory Acute Myeloid Leukemia (AML) Cancer

Acute Myeloid Leukemia (AML)

United States
Astex Pharmaceuticals, Inc.

Completed

SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction

Leukemia, Myeloid, Acute

United States, Spain, Korea, Republic of, Taiwan, Australia, Canada, Denmark, Hungary, Japan, Finland, Italy, Serbia, Czechia, France, Germany, Sweden, Netherlands, Poland, Russian Federation, Austria, United Kingdom, Romania, Belgium, Bulgar...
Hospital General de Mexico
Fresenius Kabi

Unknown

Effect of a Hyperproteic Hyperenergetic Enteral Formula on Body Composition and VEGF in AML During Hospital Stay (HEMVEF)

Acute Myeloid Leukemia, Adult

Mexico
M.D. Anderson Cancer Center

Completed

Decitabine for Older or Unfit Patients With Acute Myeloid Leukemia (AML)

Leukemia

United States
Genentech, Inc.

Completed

A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy

Leukemia, Myeloid, Acute

United States, Canada
Wuhan Union Hospital, China
Wuhan Bio-Raid Biotechnology Co., Ltd.

Unknown

Safety and Efficacy of Anti-CD123 CAR-T Therapy in Patients With Refractory/ Relapsed CD123+ Acute Myeloid Leukemia.

CD123+ Acute Myeloid Leukemia

China
Pharmacyclics LLC.

Terminated

Study of Ibrutinib in Subjects With Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML)

United States

Clinical Trials on Chronische myeloïde leukemie

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guatemala

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations